Neurocrine Biosciences (NBIX) Assets (QoQ) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Assets (QoQ) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.38 Bn | 624.62 Bn | 17.26 Bn |
| 2 | AbbVie | 443.13 Bn | 436.56 Bn | 12.70 Bn |
| 3 | Merck | 365.40 Bn | 358.26 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.79 Bn | 259.10 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.92 Bn | 43.92 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.23% |
| Mar 31, 2026 | 5.93% |
| Dec 31, 2025 | 8.58% |
| Sep 30, 2025 | 9.66% |
| Jun 30, 2025 | 5.48% |
| Mar 31, 2025 | -0.83% |
| Dec 31, 2024 | 5.20% |
| Sep 30, 2024 | 6.96% |
| Jun 30, 2024 | -4.82% |
| Mar 31, 2024 | 6.80% |
| Dec 31, 2023 | 14.16% |
| Sep 30, 2023 | 9.00% |
| Jun 30, 2023 | 10.73% |
| Mar 31, 2023 | -0.38% |
| Dec 31, 2022 | 10.51% |
| Sep 30, 2022 | 6.87% |
| Jun 30, 2022 | -6.47% |
| Mar 31, 2022 | 3.47% |
| Dec 31, 2021 | 2.74% |
| Sep 30, 2021 | 3.11% |